Motif Bio Share Discussion Threads

[someuwin] 05/6/2017 08:47

Beaufort Securities

Motif Bio (MTFB.L, 33.75p) – Speculative Buy

Motif Bio, the AIM and NASDAQ-quoted clinical stage biopharmaceutical company specialising in developing novel antibiotics, on Friday announced that it has successfully raised £20.0m (US$25.8m) by way of an issue of 66,666,667 new ordinary shares to both new and existing investors at the placing price of 30p. The placing shares will represent 34% of the issued ordinary share capital of the Company prior to the placing. The Placing Price represents a discount of 11.7% to the trailing ten day VWAP of 34p and a discount of 21.1% to the Company's mid-market closing price as at 1 June 2017. The placing remains conditional, inter alia, on the passing of certain resolutions by shareholders of the Company at a general meeting expected to be held on 22 June 2017. Upon approval, application is expected to be made for the new placing shares to be admitted to trading on AIM at 8.00 am on 23 June 2017. The new placing shares will rank pari passu with the Company's existing Ordinary Shares. Motif Bio's CEO, Graham Lumsden, commented "This financing has been well received and gives us the resources to complete the REVIVE-2 Phase 3 clinical trial and file a New Drug Application and Marketing Authorisation Application in the first half of 2018 to achieve marketing approval of iclaprim in the US and Europe. I am delighted by the support shown by our existing shareholders and also welcome a number of new institutional holders to the register".

Our view: Clouds are rapidly disappearing! Motif Bio has now secured necessary funding to complete its Phase III REVIVE-2 study for treatment of acute bacterial skin and skin structure infections ('ABSSSI'). Subject to shareholder approval, the total raise of £20.0m (US$25.8m), before expenses, will take Motif to submission of NDA (FDA) and a MAA (EMA) for its novel antibiotic candidate, iclaprim, in ABSSSI, while also provide funding for general corporate purposes. Iclaprim appears capable of creating considerable value for Motif shareholders, as seen back in 18 April 2017, where the Group announced a positive Phase III Topline Results for iclaprim in REVIVE-1 for treatment of ABSSSI. Motif is currently working on REVIVE-2, its second Phase III ABSSSI trial, which more than 80% of the total patients has now enrolled. The Board is increasingly confident as REVIVE-2 uses an identical protocol to REVIVE-1 at different trial centres. Topline Data for REVIVE-2 is expected in the H2 2017. Assuming positive results for REVIVE-2, together with REVIVE-1, this will comprise sufficient regulatory data to complete NDA submissions to both the FDA and EMA early in H1 2018. Unlike current standard of care antibiotics, in clinical trials to date, nephrotoxicity has not been observed with iclaprim and dosage adjustment has not been required in renally impaired patients. This is important, given that it is estimated that up to 26% of the 3.6 million ABSSSI patients hospitalised annually in the US have kidney disease. This suggests very significant prospective demand for this novel antibiotic. Moreover, preparations are now completed for INSPIRE, the Phase III trial designed to study the safety and efficacy of iclaprim in patients with hospital acquired bacterial pneumonia ('HABP'), including ventilator associated bacterial pneumonia (VABP), infections often caused by MRSA (methicillin resistant Staphylococcus aureus). Beaufort considers this platform antibiotic could achieve a value in excess of US$1bn following successful commercialisation of just the molecule's first two indications. Now that funding gap being fulfilled, with Motif's market capitalisation of just £65m against its most obvious comparative, Paratek Pharmaceuticals' US$567m, the giant valuation gap with its peer could rapidly close. Beaufort reiterate its Speculative Buy rating with a target price of 110p. Motif Bio is one of Beaufort's Tips for 2017.

[toolsmoker] 02/6/2017 19:27

Massive scale back for everyone so expect this to be trading back in the high 30s next week

[big_cat] 02/6/2017 16:51

30p confirmed

[backtogo] 02/6/2017 16:42

no genius to work it out at 30pprice was telling you

[letmepass] 02/6/2017 16:41

I wish IAML has committed to an investment of 16,789,994 Placing Shares at the Placing Price.

[pugugly] 02/6/2017 16:40

And the winner is .
letmepass
2 Jun '17 - 14:35 - 1247 of 1272 0 0
Placing at 30p

Insider ??????????????????????

[letmepass] 02/6/2017 16:38

RNS only 2 hours late but not bad.. 30p floor.. Should see lots of uplift from here

[letmepass] 02/6/2017 16:31

Issues with raising funds?

[123js] 02/6/2017 16:30

No US involvement which is odd given the 'efforts' to get on NASDAQ...pain not worth the glitz and glamour perhaps?...or simply part of wider strategy?

[letmepass] 02/6/2017 16:21

Nobody knows what the Placing is yet you fool

[backtogo] 02/6/2017 16:19

which of the usual rampers were pumping this then? the doc? tops?yeah yeah, the placing crew

[letmepass] 02/6/2017 15:38

If it drops to 25 it will quickly rise again

[trotterstrading] 02/6/2017 15:37

Looks like it will be after market close for a typical PI shafting

[letmepass] 02/6/2017 15:29

Expect a big jump from here then but I reckon under 30

[pugugly] 02/6/2017 15:28

Market performance on volume suggests (to me) placing price leaking and guess could be 31-32p with current holdings being sold to be repalced with lower priced placing - but what do I know - nothing !!!!!!!!!!

[letmepass] 02/6/2017 15:24

All selling done for now.. Wait and top up

[trotterstrading] 02/6/2017 15:21

How much do Mgmt hold? If they don't have much skin in the game their sole objective will be get the cash in regardless of discount?

[trotterstrading] 02/6/2017 15:18

Last time they discounted by about 35% didn't they?

[panic investor] 02/6/2017 15:18

if its at 25 there are going to be some seriously peed off investors.

[panic investor] 02/6/2017 15:17

If you say something at least bloody do it.

[trotterstrading] 02/6/2017 15:15

25p I recon